Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

For the first time, Eupraxia is reporting 24-week data on symptom response from the highest dose cohort in the open label, Phase 1b/2a portion of the RESOLVE trial. The data is important because it is from one of the two doses that are being studied in the placebo-controlled Phase 2b portion of the study.Patients in the highest dose cohort (n=3) had an average reduction of 4 points in their symptom scores compared to baseline (as measured by SDI, where a 3 point reduction is clinical remission).Across dose ...